Natalie Morrison
Family · Chesterfield, MONPI 1043747504
Payments from drug & device makers
Across 52 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$317
- AstraZeneca$131
- AbbVie$94
- Corcept Therapeutics$76
- Novartis$63
- Medtronic$62
- plus $487 from 18 others
What the payments were for
- Food & beverage$1,231100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $317 |
| AstraZeneca | 3 | $131 |
| AbbVie | 5 | $94 |
| Corcept Therapeutics | 3 | $76 |
| Novartis | 4 | $63 |
| Medtronic | 3 | $62 |
| Tandem Diabetes Care, Inc. | 1 | $61 |
| Lilly USA, LLC | 4 | $57 |
| Nevro Corp. | 3 | $46 |
| Ascendis Pharma Endocrinology Inc | 2 | $43 |
| Boehringer Ingelheim | 2 | $36 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Intuity Medical Inc | 2 | $28 |
| Sequel Med Tech, LLC | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
| Ascensia Diabetes Care US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,231 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $51,853 |
| TrulicityDulaglutide | 14 | $28,802 |
| MounjaroTirzepatide | 11 | $23,075 |
| SynthroidLevothyroxine Sodium | 26 | $1,636 |
| Ezetimibe | 19 | $432 |
| Levothyroxine Sodium | 13 | $143 |
| Atorvastatin Calcium | 12 | $105 |
| Rosuvastatin Calcium | 15 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $57 | $51,87825 claims |
| Novo NordiskOzempic | $317 | $51,85328 claims |
| AbbVieSynthroid | $94 | $1,63626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.
Other family in Chesterfield
- Sarah KeimChesterfield$35K
- Jared HuChesterfield$30K
- Whitney FeichtnerChesterfield$29K
- Jessica FaronChesterfield$13K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.